Navigation Links
New Incentives to Help Combat Antimicrobial Resistance, but Overuse of Strong Antibiotics Still Needs to Be Curbed
Date:7/12/2012

ROUND ROCK, Texas, July 12, 2012 /PRNewswire/ -- The FDA Safety Innovation Act (FDASIA), signed yesterday, provides pharmaceutical manufacturers with an extended window of antibiotic formulary exclusivity. This incentive should increase drug innovation, but it doesn't address increasing antimicrobial drug resistance, according to noted expert, Dr. David Khan of The University of Texas Southwestern Medical Center in Dallas.

"Too often, a patient's self-reported penicillin allergy causes broad antibiotics to be prescribed even though penicillin was the most appropriate treatment. However, studies show in nine out of ten cases, patients reporting a penicillin allergy are non-allergic," said Dr. Khan.

"Test before treating with non-penicillin antibiotics. With a simple, quick allergy skin test, doctors can easily and inexpensively determine if penicillin is an option," said Dr. Roland Solensky of the Corvallis Clinic.

"Overuse of broad spectrum antibiotic leads to antimicrobial resistance and the need for more powerful antibiotics, which have more toxic side effects," said Dr. Solensky, who wrote the drug allergy practice guidelines.

"By denying a potentially effective treatment, these patients are susceptible to the overuse of broad spectrum antibiotics, leading to increased drug-resistant bacteria," said Jose A. Moreno Toscano, President of ALK-Abello, Inc.

PRE-PEN® (benzylpenicilloyl polylysine injection USP), a skin test product widely used for more than 30 years, can help medical staff quickly identify patients who can safely receive penicillin, opening up a wider range of options and saving lives in the process.

About ALK
ALK holds worldwide rights to market and distribute PRE-PEN® (benzylpenicilloyl polylysine injection USP) penicillin skin testing product. PRE-PEN® (benzylpenicilloyl polylysine injection USP) is currently approved and sold in the USA and Canada.

ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is the world leader in allergy vaccination (immunotherapy), a treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. The company has approximately 1,400 employees with subsidiaries, production facilities and distributors worldwide. ALK was named one of the Best Companies to Work for in Texas in 2012 by www.BestCompaniesTX.com. Further information is available at www.alk-abello.us.

Contact Information:
Lisa Lawrence
For ALK
512-426-4904
Lisa.Lawrence@hcbhealth.com


'/>"/>
SOURCE ALK
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Hong Kong Department of Health to Combat Sudden Cardiac Arrest With Powerheart AEDs
2. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
3. The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.s Technology in Combating Colony Collapse Disorder
4. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
5. UN emission market needs urgent reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... Market Research "Metabolomics Market - Global Industry Analysis, Size, ... metabolomics market is anticipated to expand at a CAGR ... 2,494.8 million by 2024. Metabolomics is the ... within cells, biofluids, tissues or organisms. Together, these small ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... innovations in biotechnology to help treat hormonal and stress related hair loss. With ... captured the hearts of key opinion leaders in the medical and salon channels ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... enterprise talent development, skill-building and compliance training platform on mobile devices, today released ... Overview of Regulatory Requirements for Medical Devices. The course is essential for owners ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... CEO 2016 on May 31st and June 1st at The Four Seasons Hotel ... executives in the life sciences, offering exclusive access to key decision makers who ...
Breaking Biology Technology:
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
(Date:3/11/2016)... , March 11, 2016 http://www.apimages.com ) ... Cross reference: Picture is available at AP Images ( http://www.apimages.com ) ... DERMALOG will be used to produce the new refugee identity cards. ... biometric innovations, at CeBIT in Hanover next ... from DERMALOG will be used to produce the new refugee identity ...
Breaking Biology News(10 mins):